Artwork

Indhold leveret af Clinical Care Options, LLC and Clinical Care Options. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Clinical Care Options, LLC and Clinical Care Options eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !

ROS1-Alterations and Molecular Testing in Advanced NSCLC

16:28
 
Del
 

Manage episode 436715992 series 3256997
Indhold leveret af Clinical Care Options, LLC and Clinical Care Options. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Clinical Care Options, LLC and Clinical Care Options eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the current understanding of ROS1 rearrangements in non-small-cell lung cancer tumor biology and its implications for molecular testing and treatment selection including:

  • ROS1-gene fusions in advanced lung cancer
  • ROS1 testing recommendations with DNA NGS, RNA NGS, FISH break apart assay, and IHC
  • Comparative specificity of ROS1 and ALK targeting tyrosine kinase inhibitors
  • Advantages of RNA- vs DNA-based next-generation sequencing

Program faculty:

Jessica J. Lin, MD
Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Alice T. Shaw, MD, PhD
Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Resources:

To download the slides associated with this podcast discussion, please visit the program page

  continue reading

181 episoder

Artwork
iconDel
 
Manage episode 436715992 series 3256997
Indhold leveret af Clinical Care Options, LLC and Clinical Care Options. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Clinical Care Options, LLC and Clinical Care Options eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the current understanding of ROS1 rearrangements in non-small-cell lung cancer tumor biology and its implications for molecular testing and treatment selection including:

  • ROS1-gene fusions in advanced lung cancer
  • ROS1 testing recommendations with DNA NGS, RNA NGS, FISH break apart assay, and IHC
  • Comparative specificity of ROS1 and ALK targeting tyrosine kinase inhibitors
  • Advantages of RNA- vs DNA-based next-generation sequencing

Program faculty:

Jessica J. Lin, MD
Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Alice T. Shaw, MD, PhD
Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Resources:

To download the slides associated with this podcast discussion, please visit the program page

  continue reading

181 episoder

Όλα τα επεισόδια

×
 
Loading …

Velkommen til Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Hurtig referencevejledning